Cargando…

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51 countries during 2019. Main indications were myeloid malign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passweg, Jakob R., Baldomero, Helen, Chabannon, Christian, Basak, Grzegorz W., de la Cámara, Rafael, Corbacioglu, Selim, Dolstra, Harry, Duarte, Rafael, Glass, Bertram, Greco, Raffaella, Lankester, Arjan C., Mohty, Mohamad, Peffault de Latour, Régis, Snowden, John A., Yakoub-Agha, Ibrahim, Kröger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263343/ https://www.ncbi.nlm.nih.gov/pubmed/33623153 http://dx.doi.org/10.1038/s41409-021-01227-8

Ejemplares similares

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020)

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
por: Passweg, Jakob R., et al.
Publicado: (2022)

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
por: Snowden, John A., et al.
Publicado: (2022)

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
por: Passweg, Jakob R., et al.
Publicado: (2023)

Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2023)

The first steps towards a diverse and inclusive EBMT: a position paper
por: Montoto, S., et al.
Publicado: (2022)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2020)

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Saccardi, Riccardo, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
por: Passweg, Jakob R, et al.
Publicado: (2018)

The coming of age of the pediatric EBMT criteria
por: Corbacioglu, Selim
Publicado: (2020)

Correction to: The coming of age of the pediatric EBMT criteria
por: Corbacioglu, Selim
Publicado: (2021)

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2023)

P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
por: Basak, G., et al.
Publicado: (2022)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
por: Penack, Olaf, et al.
Publicado: (2023)

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
por: Ruggeri, Annalisa, et al.
Publicado: (2016)

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2021)

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations
por: Greco, Raffaella, et al.
Publicado: (2021)

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2018)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
por: Miller, Paul D. E., et al.
Publicado: (2019)

Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties
por: Greco, Raffaella, et al.
Publicado: (2019)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
por: Raj, Kavita, et al.
Publicado: (2022)

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study
por: Ruutu, Tapani, et al.
Publicado: (2023)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
por: Styczyński, Jan, et al.
Publicado: (2019)

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities
por: Ellard, Rose, et al.
Publicado: (2022)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT
por: Ghorashian, Sara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k7m0dkmac7tqc18el0t8k4uk21